Literature DB >> 15269159

Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus.

Hidenobu Ochiai1, Stephanie A Moore, Gary E Archer, Tatsunori Okamura, Tracy A Chewning, Jeffrey R Marks, John H Sampson, Matthias Gromeier.   

Abstract

PURPOSE: Spread to the central nervous system (CNS) and the leptomeninges is a frequent complication of systemic cancers that is associated with serious morbidity and high mortality. We have evaluated a novel therapeutic approach against CNS complications of breast cancer based on the human neuropathogen poliovirus (PV). EXPERIMENTAL
DESIGN: Susceptibility to PV infection and ensuing rapid cell lysis is mediated by the cellular receptor of PV, CD155. We evaluated CD155 expression in several human breast tumor tissue specimens and cultured breast cancer cell lines. In addition, we tested an oncolytic PV recombinant for efficacy in xenotransplantation models of neoplastic meningitis and cerebral metastasis secondary to breast cancer.
RESULTS: We observed that breast cancer tissues and cell lines derived thereof express CD155 at levels mediating exquisite sensitivity toward PV-induced oncolysis in the latter. An association with the immunoglobulin superfamily molecule CD155 renders breast cancer a likely target for oncolytic PV recombinants. This assumption was confirmed in xenotransplantation models for neoplastic meningitis or solitary cerebral metastasis, where local virus treatment dramatically improved survival.
CONCLUSIONS: Our findings suggest oncolytic PV recombinants as a viable treatment option for CNS complications of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15269159     DOI: 10.1158/1078-0432.CCR-03-0694

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

Review 1.  Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Authors:  Christian Goetz; Matthias Gromeier
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-17       Impact factor: 7.638

2.  The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.

Authors:  Huijun Zhao; Juan Ma; Ting Lei; Wanru Ma; Man Zhang
Journal:  Invest New Drugs       Date:  2018-10-29       Impact factor: 3.850

3.  The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the rhinovirus type 2 internal ribosome entry site.

Authors:  Melinda K Merrill; Matthias Gromeier
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

4.  A host-specific, temperature-sensitive translation defect determines the attenuation phenotype of a human rhinovirus/poliovirus chimera, PV1(RIPO).

Authors:  Nusrat Jahan; Eckard Wimmer; Steffen Mueller
Journal:  J Virol       Date:  2011-05-11       Impact factor: 5.103

5.  Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.

Authors:  Baobiao Zhuo; Yuan Li; Feng Gu; Zhengwei Li; Qingzeng Sun; Yingchun Shi; Yang Shen; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2018-03-09       Impact factor: 2.967

6.  Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay.

Authors:  Xiaoyi Yang; Eying Chen; Hengguang Jiang; Karen Muszynski; Raymond D Harris; Steven L Giardina; Matthias Gromeier; Gautam Mitra; Gopalan Soman
Journal:  J Virol Methods       Date:  2008-11-08       Impact factor: 2.014

Review 7.  Oncolytic polio virotherapy of cancer.

Authors:  Michael C Brown; Elena Y Dobrikova; Mikhail I Dobrikov; Ross W Walton; Sarah L Gemberling; Smita K Nair; Annick Desjardins; John H Sampson; Henry S Friedman; Allan H Friedman; Douglas S Tyler; Darell D Bigner; Matthias Gromeier
Journal:  Cancer       Date:  2014-06-17       Impact factor: 6.860

8.  Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors.

Authors:  Yushui Wu; Xueqing Lun; Hongyuan Zhou; Limei Wang; Beichen Sun; John C Bell; John W Barrett; Grant McFadden; Jaclyn A Biegel; Donna L Senger; Peter A Forsyth
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

9.  Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76.

Authors:  Melinda K Merrill; Elena Y Dobrikova; Matthias Gromeier
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.

Authors:  Zhuwei Xu; Tao Zhang; Ran Zhuang; Yun Zhang; Wei Jia; Chaojun Song; Kun Yang; Angang Yang; Boquan Jin
Journal:  BMC Immunol       Date:  2009-06-02       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.